glp-1 pearls Probiotic for Weight Support Clinical Pearls for Individualizing T2DM

The Role of Lifestyle Modification with Second-Generation Anti-obesity Medications: Comparisons, Questions, and Clinical Opportunities

Genetic variants in SGLT1, glucose tolerance, and cardiometabolic risk

Key players driving the GLP-1 market include Novo Nordisk, Eli Lilly, Pfizer, AstraZeneca, Roche, Sanofi, Boehringer Ingelheim, and Tonghua Dongbao Pharmaceutical

Clinical wins, safety setbacks, generics pressure, and aggressive IP maneuvering are reshaping the competitive landscape at record speed

For a direct comparison of weight management and blood sugar control across the main GLP-1 options, our detailed guide on Wegovy, Ozempic, and Mounjaro breaks it down clearly